Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EP Technologies Inc.

Division of Boston Scientific Corp.

Latest From EP Technologies Inc.

Bard EP Deal Latest In Boston Scientific’s M&A Revival, Bolsters CRM Business

Boston Scientific’s recent acquisition of Bard Electrophysiology marks the tenth notable acquisition that it has made since 2010. Four of those deals come in cardiac rhythm management, including EP, which is among the fastest-growing device sectors and one that company executives see as a major contributor to future growth.

Medical Device Deals

AtriCure: Making Order Out Of Chaos

Atrial fibrillation (AF), once thought of as a benign condition affecting a relatively small patient population, has recently been found to be a major contributor to stroke and congestive heart failure (CHF), and is expected to afflict a much larger patient pool, particularly as the population ages, making AF one of the largest unmet cardiovascular clinical opportunities. The only current cure for AF is a traumatic, rarely performed surgical procedure. Palliative treatments are limited to drug regimens that are often ineffective and can produce serious side effects; or electrophysiology and cardiac rhythm management procedures that are only used for a relatively small number of patients. The size of the AF patient market and the recent discovery that AF is a precursor to stroke and CHF have elevated the condition in importance to product companies, making it one of the most competitive areas for the next generation of cardiovascular devices, and attracting interest from all the major cardiology companies, as well as many start-ups. AtriCure is developing novel technology that for the first time enables surgeons to ensure they are producing lesions that are transmural, meaning they completely penetrate the cardiac tissue. Transmural lesions have been shown to provide the only effective means of curing AF. The company's first-mover advantage puts it ahead of the pack, at least for now. AtriCure's challenge is to expand the application of its technology to avoid being marginalized when the inevitable rush of big and small players enter the market.
Medical Device Strategy

Springflex Orthopedics Inc.

Springflex Orthopedics Inc. is using the superelastic memory shape metal alloy, nickel titanium (Nitinol), as a material for anatomic braces. Nitinol provides stabilization and support while allowing more natural movement than conventional braces made with elastic or semi-rigid polymer metal alloy supports, because it can withstand much greater strain levels and still spring back to its initial annealed configuration.
Medical Device Innovation

Boston Scientific's Buying Spree Continues, This Time in EP

This month's $115 million cash deal to acquire electrophysiology company Cardiac Pathways Corp., makes five acquisitions for Boston Scientific already this year. Boston's dealmaking flurry is particularly notable given the relative inactivity of other large device companies on the acquisition front, and the cold shoulder the public market has given to the device sector. This deal reflects Boston's renewed commitment to electrophysiology, an area the company was thinking about exiting just a couple of years ago despite having a market-leading product. But it still remains to be seen whether this recent string of deals can turn around Boston Scientific and boost its flagging stock price.
Medical Device Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Boston Scientific Corp.
  • Senior Management
  • Terry E Spraker, PhD, Pres. & CEO
  • Contact Info
  • EP Technologies Inc.
    Phone: (408) 481-3800
    350 Potrero Ave.
    Sunnyvale, CA 94086
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register